Market Closed -
Bombay S.E.
11:00:54 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
1,104
INR
|
+0.35%
|
|
+1.47%
|
+42.77%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
15,118
|
16,933
|
12,401
|
13,629
|
14,579
|
13,958
|
Enterprise Value (EV)
1 |
7,383
|
10,828
|
7,280
|
9,280
|
9,656
|
8,629
|
P/E ratio
|
21.5
x
|
32.7
x
|
123
x
|
65.2
x
|
-392
x
|
13.5
x
|
Yield
|
1.63%
|
1.46%
|
1.99%
|
1.81%
|
1.69%
|
1.77%
|
Capitalization / Revenue
|
2.68
x
|
3.45
x
|
2.83
x
|
3.57
x
|
3.65
x
|
3.69
x
|
EV / Revenue
|
1.31
x
|
2.21
x
|
1.66
x
|
2.43
x
|
2.41
x
|
2.28
x
|
EV / EBITDA
|
-125
x
|
68.4
x
|
154
x
|
51.9
x
|
37.6
x
|
14
x
|
EV / FCF
|
6.02
x
|
-6.5
x
|
63.1
x
|
-18.4
x
|
7.95
x
|
15.2
x
|
FCF Yield
|
16.6%
|
-15.4%
|
1.58%
|
-5.44%
|
12.6%
|
6.58%
|
Price to Book
|
2.06
x
|
2.23
x
|
1.72
x
|
1.92
x
|
2.11
x
|
1.8
x
|
Nbr of stocks (in thousands)
|
24,691
|
24,691
|
24,691
|
24,691
|
24,691
|
24,691
|
Reference price
2 |
612.3
|
685.8
|
502.2
|
552.0
|
590.4
|
565.3
|
Announcement Date
|
02/08/18
|
08/07/19
|
10/07/20
|
30/07/21
|
30/06/22
|
30/06/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,639
|
4,907
|
4,382
|
3,814
|
3,999
|
3,787
|
EBITDA
1 |
-59
|
158.3
|
47.3
|
178.9
|
256.5
|
618.4
|
EBIT
1 |
-84.3
|
126.5
|
8.4
|
147.7
|
237.7
|
600.8
|
Operating Margin
|
-1.49%
|
2.58%
|
0.19%
|
3.87%
|
5.94%
|
15.86%
|
Earnings before Tax (EBT)
1 |
1,575
|
857.7
|
286.4
|
400.4
|
-38.2
|
1,154
|
Net income
1 |
783.6
|
517.7
|
100.8
|
209
|
-37.2
|
1,034
|
Net margin
|
13.9%
|
10.55%
|
2.3%
|
5.48%
|
-0.93%
|
27.29%
|
EPS
2 |
28.43
|
20.97
|
4.082
|
8.465
|
-1.507
|
41.86
|
Free Cash Flow
1 |
1,226
|
-1,667
|
115.3
|
-504.7
|
1,215
|
568.2
|
FCF margin
|
21.74%
|
-33.97%
|
2.63%
|
-13.23%
|
30.37%
|
15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
243.79%
|
-
|
473.52%
|
91.88%
|
FCF Conversion (Net income)
|
156.46%
|
-
|
114.4%
|
-
|
-
|
54.97%
|
Dividend per Share
2 |
10.00
|
10.00
|
10.00
|
10.00
|
10.00
|
10.00
|
Announcement Date
|
02/08/18
|
08/07/19
|
10/07/20
|
30/07/21
|
30/06/22
|
30/06/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7,735
|
6,105
|
5,121
|
4,349
|
4,923
|
5,329
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,226
|
-1,667
|
115
|
-505
|
1,215
|
568
|
ROE (net income / shareholders' equity)
|
9.48%
|
6.94%
|
1.36%
|
2.92%
|
-0.53%
|
14.1%
|
ROA (Net income/ Total Assets)
|
-0.47%
|
0.76%
|
0.05%
|
0.89%
|
1.52%
|
3.87%
|
Assets
1 |
-168,118
|
68,524
|
198,035
|
23,547
|
-2,454
|
26,707
|
Book Value Per Share
2 |
297.0
|
307.0
|
292.0
|
288.0
|
280.0
|
314.0
|
Cash Flow per Share
2 |
15.20
|
35.50
|
32.00
|
27.60
|
64.10
|
7.870
|
Capex
1 |
8
|
141
|
10
|
0.9
|
5
|
3.1
|
Capex / Sales
|
0.14%
|
2.87%
|
0.23%
|
0.02%
|
0.13%
|
0.08%
|
Announcement Date
|
02/08/18
|
08/07/19
|
10/07/20
|
30/07/21
|
30/06/22
|
30/06/23
|
|
1st Jan change
|
Capi.
|
---|
| +42.77% | 327M | | +55.32% | 815B | | +44.05% | 641B | | -6.75% | 352B | | +13.56% | 314B | | +10.68% | 303B | | +16.57% | 242B | | +13.31% | 218B | | +8.48% | 168B | | -2.81% | 159B |
Other Pharmaceuticals
|